直接口服抗凝药对房颤口服抗凝率的影响
本研究基于美国PINNACLE注册研究,纳入655,000例CHA2DS2-VASc评分>1的非瓣膜性房颤患者,分析2008年4月至2014年9月间直接口服抗凝药(DOAC)可用性对整体口服抗凝(OAC)率的影响。结果显示整体OAC率从52.4%升至60.7%,华法林使用从52.4%降至34.8%,DOAC从0%升至25.8%,但仍有显著差距且存在实践差异。
要点
- DOAC可用后整体OAC率从52.4%升至60.7%,华法林从52.4%降至34.8%,DOAC从0%升至25.8%。
- CHA2DS2-VASc评分升高与OAC使用增加相关(OR 1.06),但与DOAC使用减少相关(OR 0.97)。
- OAC使用存在显著实践差异(MOR 1.52),DOAC使用差异更大(MOR 3.58)。
核心结论
- DOAC进入常规实践与房颤整体OAC率改善相关,但仍有显著差距,且OAC和DOAC使用存在显著实践层面差异。
研究设计与样本
- 回顾性分析美国国家心血管数据注册PINNACLE注册研究,2008年4月1日至2014年9月30日纳入655,000例CHA2DS2-VASc评分>1的非瓣膜性房颤患者。
主要发现
- 整体OAC率从52.4%升至60.7%(趋势p<0.01)。
- 华法林使用从52.4%降至34.8%(趋势p<0.01),DOAC使用从0%升至25.8%(趋势p<0.01)。
- CHA2DS2-VASc评分升高与OAC使用增加相关(OR 1.06;95%CI 1.05-1.07),但与DOAC使用减少相关(OR 0.97;95%CI 0.96-0.98)。
- OAC使用存在显著实践差异(MOR 1.52;95%CI 1.45-1.57),DOAC使用差异更大(MOR 3.58;95%CI 3.05-4.13)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF). The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF patients, but a large-scale evaluation of their effects has not been conducted. OBJECTIVES: This study assessed the effect of DOAC availability on overall OAC rates for nonvalvular AF. METHODS: Between April 1, 2008 and September 30, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the National Cardiovascular Data Registry PINNACLE registry. Temporal trends in overall OAC and individual warfarin and DOAC use were analyzed. Multivariable hierarchical logistic regression identified patient factors associated with OAC and DOAC use. Practice variation of OAC and DOAC use was also assessed. RESULTS: Overall OAC rates increased from 52.4% to 60.7% among eligible AF patients (p for trend <0.01). Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25.8% (p for trend <0.01). An increasing CHA2DS2-VASc score was associated with higher OAC use (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05 to 1.07), but with lower DOAC use (OR: 0.97; 95% CI: 0.96 to 0.98). Significant practice variation was present in OAC use (median odds ratio [MOR]: 1.52; 95% CI: 1.45 to 1.57) and in DOAC use (MOR: 3.58; 95% CI: 3.05 to 4.13). CONCLUSIONS: Introduction of DOACs in routine practice was associated with improved rates of overall OAC use for AF, but significant gaps remain. In addition, there is significant practice-level variation in OAC and DOAC use.
引用
- Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2017. PMID: 28521884. doi:10.1016/j.jacc.2017.03.540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。